ClinicalTrials.gg
CompletedNCT00558428Updated Jun 27, 2014Results posted

Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension

A Phase 3 interventional study of fixed dose combination of telmisartan+amlodipine and amlodipine in Hypertension, sponsored by Boehringer Ingelheim. Completed at 129 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-27.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,098
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
22nd of 186
1,098 · median 180
Started
2007
with 16 others
Phase 3
69 of 187
2 open now
Registered
52nd of 187
by date
Lead sponsor
12 of 187
Boehringer Ingelheim

Among the 187 studies testing amlodipine in Hypertension, this one is the 22nd largest by enrollment of the 186 interventional ones that give a count, is one of 17 that started in 2007, is one of 69 in phase 3, and was the 52nd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

The primary objectives of this trial are (a) to demonstrate that the fixed-dose combination T40/A5 or the fixed-dose combination T80/A5 is superior in reducing blood pressure at eight weeks compared with A5 (b) to demonstrate that the fixed-dose combination T40/A5 or the fixed-dose combination T80/A5 is not inferior in reducing blood pressure at eight weeks compared with A10 and (c) to demonstrate that the incidence of oedema on the fixed-dose combination T40/A5 pooled with the fixed-dose combination T80/A5 is superior (less oedema) to A10 in patients who fail to respond adequately to six weeks treatment with A5.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients aged at least 18 years at the date of signing the consent form
  2. diagnosis of essential hypertension and blood pressure not adequately controlled before enrolment in the study
  3. failure to respond adequately to six weeks treatment with amlodipine 5 mg monotherapy
  4. able to stop any current antihypertensive therapy without unacceptable risk to the patient (Investigator's decision)
  5. willing and able to provide written (in accordance with Good Clinical Practice and local legislation).

Exclusion criteria

Exclusion Criteria:

  1. are not practising acceptable means of or do not plan to continue using acceptable means of birth control throughout the study and do not agree to submit to pregnancy testing during participation in the trial. Acceptable methods of birth control include the transdermal patch, oral, implantable or injectable contraceptives, sexual abstinence and vasectomised partner.
  2. known or suspected secondary hypertension
  3. mean seated systolic blood pressure (SBP) over 200 mmHg and/or mean seated diastolic blood pressure (DBP) over 120 mmHg at Visit 1 or 2 or mean seated SBP over 180 mmHg and/or mean seated DBP over 120 mmHg at the end of the run-in period (Visit 3)
  4. any hepatic impairment (e.g. clinically significant cholestasis, biliary obstructive disorder or hepatic insufficiency)
  5. severe renal impairment (e.g. serum creatinine >3.0 mg/dL or >265 mcmol/L, known \<30mL/min or clinical markers of severe renal impairment)
  6. bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post-renal transplant
  7. clinically relevant hyperkalaemia
  8. uncorrected volume or sodium depletion.
  9. primary aldosteronism.
  10. hereditary fructose or lactose intolerance
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Intervention model
Parallel assignment
Enrollment
1,098 participants (actual)

Interventions

  • Drugfixed dose combination of telmisartan+amlodipine
06

What researchers measure

Primary outcomes

  1. Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP)

    Change from baseline to the end of study in trough DBP

    Time frame: End of study (8 weeks or last value on treatment)

  2. Number of Patients With Oedema

    Patients from the treated set who experienced at least one case of general oedema.

    Time frame: During randomised treatment period (8 weeks was the planned end of treatment, some of the measurements analysed as end of study can be at 4 weeks or at any point on randomised treatment)

Secondary outcomes

  1. Change From Baseline in Trough Seated Systolic Blood Pressure (SBP)

    Change from baseline to the end of study in trough SBP

    Time frame: End of study (8 weeks or last value on treatment)

  2. Trough Seated Diastolic Blood Pressure Control

    The number of patients who reach the target DBP of \<90mmHg

    Time frame: End of study (8 weeks or last value on treatment)

  3. Trough Seated DBP Response

    The number of patients who reach the target DBP of \<90mmHg or had a reduction in DBP \>= 10mmHg

    Time frame: End of study (8 weeks or last value on treatment)

  4. Trough Seated SBP Control

    The number of patients who reach the target SBP of \<140mmHg

    Time frame: End of study (8 weeks or last value on treatment)

  5. Trough Seated SBP Response

    The number of patients who reach the target SBP of \<140mmHg or had a reduction in SBP \>= 15 mmHg

    Time frame: End of study (8 weeks or last value on treatment)

  6. Trough Seated Blood Pressure (BP) Normality Classes

    The number of patients who reach predefined BP categories: * Optimal - SBP\<120 and DBP\<80 mmHg * Normal - SBP\<130 and DBP\<85 mmHg * High-normal - SBP\<140 DBP\<90 mmHg * Stage 1 hypertension - SBP\<160 and DBP\<100 * Stage 2 hypertension SBP\>=160 and DBP\>=100 mmHg

    Time frame: End of study (8 weeks or last value on treatment)

07

Results

Posted Dec 15, 2009

Participant flow

Participant flow — Overall Study
MilestoneAmlodipine 5mgAmlodipine 10mgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mg
Started267276277277
Completed255252273266
Not completed1224411
Withdrew: Adverse event62234
Withdrew: Lost to follow-up0100
Withdrew: Lack of efficacy0012
Withdrew: Non compliant with protocol1003
Withdrew: Consent withdrawn2101
Withdrew: Other3001

Outcome measures

PrimaryChange From Baseline in Trough Seated Diastolic Blood Pressure (DBP)

Change from baseline to the end of study in trough DBP

Time frame:
End of study (8 weeks or last value on treatment)
Reported as:
Least squares mean · mmHg
Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP)
mmHgAmlodipine 5mgAmlodipine 10mgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mg
Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP)-5.71 ± 0.49-7.95 ± 0.49-9.35 ± 0.48-10.63 ± 0.48
Statistical analysis
  • Amlodipine 5mg vs Telmisartan 40mg and Amlodipine 5mg · ANCOVA · p = <0.0001 · Least squares mean difference: -3.64 · 95% CI -4.90 to -2.38Adjusted for baseline and country effect
  • Amlodipine 5mg vs Telmisartan 80mg and Amlodipine 5mg · ANCOVA · p = <0.0001 · Least squares mean difference: -4.92 · 95% CI -6.18 to -3.66Adjusted for baseline and country effect
  • Amlodipine 10mg vs Telmisartan 40mg and Amlodipine 5mg · ANCOVA · Least squares mean difference: -1.40 · 95% CI -2.66 to -0.14Adjusted for baseline and country effect
  • Amlodipine 10mg vs Telmisartan 80mg and Amlodipine 5mg · ANCOVA · Least squares mean difference: -2.68 · 95% CI -3.93 to -1.43Adjusted for baseline and country effect
SecondaryChange From Baseline in Trough Seated Systolic Blood Pressure (SBP)

Change from baseline to the end of study in trough SBP

Time frame:
End of study (8 weeks or last value on treatment)
Reported as:
Least squares mean · mmHg
Change From Baseline in Trough Seated Systolic Blood Pressure (SBP)
mmHgAmlodipine 5mgAmlodipine 10mgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mg
Change From Baseline in Trough Seated Systolic Blood Pressure (SBP)-6.18 ± 0.73-11.11 ± 0.72-13.56 ± 0.71-14.99 ± 0.71
SecondaryTrough Seated Diastolic Blood Pressure Control

The number of patients who reach the target DBP of \<90mmHg

Time frame:
End of study (8 weeks or last value on treatment)
Reported as:
Number · patients
Trough Seated Diastolic Blood Pressure Control
patientsAmlodipine 5mgAmlodipine 10mgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mg
Yes (DBP<90 mmHg)107148153173
No (DBP>=90 mmHg)14811311798
SecondaryTrough Seated DBP Response

The number of patients who reach the target DBP of \<90mmHg or had a reduction in DBP \>= 10mmHg

Time frame:
End of study (8 weeks or last value on treatment)
Reported as:
Number · patients
Trough Seated DBP Response
patientsAmlodipine 5mgAmlodipine 10mgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mg
Yes (Responder)116163177187
No (Non-responder)139989384
SecondaryTrough Seated SBP Control

The number of patients who reach the target SBP of \<140mmHg

Time frame:
End of study (8 weeks or last value on treatment)
Reported as:
Number · patients
Trough Seated SBP Control
patientsAmlodipine 5mgAmlodipine 10mgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mg
Yes (SBP<140 mmHg)100142162178
No (SBP>=140 mmHg)15511910893
SecondaryTrough Seated SBP Response

The number of patients who reach the target SBP of \<140mmHg or had a reduction in SBP \>= 15 mmHg

Time frame:
End of study (8 weeks or last value on treatment)
Reported as:
Number · patients
Trough Seated SBP Response
patientsAmlodipine 5mgAmlodipine 10mgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mg
Yes (Responder)118166187200
No (Non-responder)137958371
SecondaryTrough Seated Blood Pressure (BP) Normality Classes

The number of patients who reach predefined BP categories: * Optimal - SBP\<120 and DBP\<80 mmHg * Normal - SBP\<130 and DBP\<85 mmHg * High-normal - SBP\<140 DBP\<90 mmHg * Stage 1 hypertension - SBP\<160 and DBP\<100 * Stage 2 hypertension SBP\>=160 and DBP\>=100 mmHg

Time frame:
End of study (8 weeks or last value on treatment)
Reported as:
Number · patients
Trough Seated Blood Pressure (BP) Normality Classes
patientsAmlodipine 5mgAmlodipine 10mgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mg
Optimal251921
Normal23303551
High-normal42686367
Stage 1 hypertension118126127110
Stage 2 hypertension70322622
PrimaryNumber of Patients With Oedema

Patients from the treated set who experienced at least one case of general oedema.

Time frame:
During randomised treatment period (8 weeks was the planned end of treatment, some of the measurements analysed as end of study can be at 4 weeks or at any point on randomised treatment)
Reported as:
Number · patients
Number of Patients With Oedema
patientsAmlodipine 5mgAmlodipine 10mgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mg
Number of patients with any oedema23761410
Number of patients with general oedema23751410

Adverse events

Collected over From day of first dose until one day after last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Amlodipine 5mg—2/267 (0.7%)22/267 (8.2%)
Amlodipine 10mg—1/276 (0.4%)74/276 (26.8%)
Telmisartan 40mg and Amlodipine 5mg—2/277 (0.7%)14/277 (5.1%)
Telmisartan 80mg and Amlodipine 5mg—1/277 (0.4%)10/277 (3.6%)
Most frequent serious events
Most frequent serious events
EventAmlodipine 5mgAmlodipine 10mgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mg
Atrial fibrilationCardiac disorders1/2670/2760/2770/277
Chest painGeneral disorders1/2670/2760/2770/277
Breast massReproductive system and breast disorders0/2671/2760/2770/277
Chest discomfortGeneral disorders0/2670/2760/2771/277
PneumoniaInfections and infestations0/2670/2761/2770/277
Bronchial carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2670/2761/2770/277
Most frequent other events
Most frequent other events
EventAmlodipine 5mgAmlodipine 10mgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mg
Oedema peripheralGeneral disorders22/26774/27614/27710/277

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Amlodipine 5mgAmlodipine 10mgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mgTotal
Mean54 ± 10.654.3 ± 10.653.9 ± 1154.5 ± 10.254.2 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Amlodipine 5mgAmlodipine 10mgTelmisartan 40mg and Amlodipine 5mgTelmisartan 80mg and Amlodipine 5mgTotal
Female10410011794415
Male163176160183682
08

Study locations

129 sites
  • 1235.5.32004 Boehringer Ingelheim Investigational Site
    Aywaille, Belgium
  • 1235.5.32001 Boehringer Ingelheim Investigational Site
    Bruxelles, Belgium
  • 1235.5.32010 Boehringer Ingelheim Investigational Site
    Gozée, Belgium
  • 1235.5.32008 Boehringer Ingelheim Investigational Site
    Linkebeek, Belgium
  • 1235.5.32003 Boehringer Ingelheim Investigational Site
    Mol, Belgium
  • 1235.5.32007 Boehringer Ingelheim Investigational Site
    Natoye, Belgium
  • 1235.5.32009 Boehringer Ingelheim Investigational Site
    Tavier, Belgium
  • 1235.5.32002 Boehringer Ingelheim Investigational Site
    Tienen-Kumtich, Belgium
  • 1235.5.32005 Boehringer Ingelheim Investigational Site
    Turnhout, Belgium
  • 1235.5.20001 Boehringer Ingelheim Investigational Site
    Coquitlam, British Columbia, Canada
  • 1235.5.20011 Boehringer Ingelheim Investigational Site
    Vancouver, British Columbia, Canada
  • 1235.5.20007 Boehringer Ingelheim Investigational Site
    Bay Roberts, Newfoundland and Labrador, Canada
  • 1235.5.20005 Boehringer Ingelheim Investigational Site
    Mount Pearl, Newfoundland and Labrador, Canada
  • 1235.5.20008 Boehringer Ingelheim Investigational Site
    St. John's, Newfoundland and Labrador, Canada
  • 1235.5.20013 Boehringer Ingelheim Investigational Site
    Corunna, Ontario, Canada
  • 1235.5.20014 Boehringer Ingelheim Investigational Site
    Etobicoke, Ontario, Canada
  • 1235.5.20010 Boehringer Ingelheim Investigational Site
    Hamilton, Ontario, Canada
  • 1235.5.20012 Boehringer Ingelheim Investigational Site
    London, Ontario, Canada
  • 1235.5.20009 Boehringer Ingelheim Investigational Site
    Ottawa, Ontario, Canada
  • 1235.5.20006 Boehringer Ingelheim Investigational Site
    Sarnia, Ontario, Canada
  • 1235.5.20003 Boehringer Ingelheim Investigational Site
    Sainte-Foy, Quebec, Canada
  • 1235.5.45002 Boehringer Ingelheim Investigational Site
    Birkerød, Denmark
  • 1235.5.45005 Boehringer Ingelheim Investigational Site
    Haderslev, Denmark
  • 1235.5.45008 Boehringer Ingelheim Investigational Site
    Herning, Denmark
  • 1235.5.45009 Boehringer Ingelheim Investigational Site
    Hinnerup, Denmark
  • 1235.5.45001 Boehringer Ingelheim Investigational Site
    Rødovre, Denmark
  • 1235.5.45006 Boehringer Ingelheim Investigational Site
    Rødovre, Denmark
  • 1235.5.45003 Boehringer Ingelheim Investigational Site
    Vaerløse, Denmark
  • 1235.5.45007 Boehringer Ingelheim Investigational Site
    Vildbjerg, Denmark
  • 1235.5.35003 Boehringer Ingelheim Investigational Site
    Joensuu, Finland
  • 1235.5.35004 Boehringer Ingelheim Investigational Site
    Joensuu, Finland
  • 1235.5.35001 Boehringer Ingelheim Investigational Site
    Turku, Finland
  • 1235.5.35002 Boehringer Ingelheim Investigational Site
    Turku, Finland
  • 1235.5.3301H Boehringer Ingelheim Investigational Site
    Aigrefeuille S/Maine, France
  • 1235.5.3306C Boehringer Ingelheim Investigational Site
    Angers, France
  • 1235.5.3309B Boehringer Ingelheim Investigational Site
    Angers, France
  • 1235.5.3309C Boehringer Ingelheim Investigational Site
    Angers, France
  • 1235.5.3309E Boehringer Ingelheim Investigational Site
    Angers, France
  • 1235.5.3309D Boehringer Ingelheim Investigational Site
    Avrille, France
  • 1235.5.3309A Boehringer Ingelheim Investigational Site
    Beaucouze, France
  • 1235.5.3305A Boehringer Ingelheim Investigational Site
    Bourg des cptes, France
  • 1235.5.3306D Boehringer Ingelheim Investigational Site
    Briollay, France
  • 1235.5.3308B Boehringer Ingelheim Investigational Site
    Cholet, France
  • 1235.5.3308C Boehringer Ingelheim Investigational Site
    Cholet, France
  • 1235.5.3308D Boehringer Ingelheim Investigational Site
    Cholet, France
  • 1235.5.3308F Boehringer Ingelheim Investigational Site
    Cholet, France
  • 1235.5.3302C Boehringer Ingelheim Investigational Site
    Garchizy, France
  • 1235.5.3303C Boehringer Ingelheim Investigational Site
    Grandchamps, France
  • 1235.5.3302D Boehringer Ingelheim Investigational Site
    Guerigny, France
  • 1235.5.3310A Boehringer Ingelheim Investigational Site
    Jarny, France
  • 1235.5.3301L Boehringer Ingelheim Investigational Site
    La Chapelle /s Erdre, France
  • 1235.5.3301J Boehringer Ingelheim Investigational Site
    La Chapelle sur Erdre, France
  • 1235.5.3304A Boehringer Ingelheim Investigational Site
    La Fresnais, France
  • 1235.5.3308E Boehringer Ingelheim Investigational Site
    La Jubaudière, France
  • 1235.5.3301G Boehringer Ingelheim Investigational Site
    La Montagne, France
  • 1235.5.3303B Boehringer Ingelheim Investigational Site
    Le Bono, France
  • 1235.5.3307D Boehringer Ingelheim Investigational Site
    Le Mesnil en Vallée, France
  • 1235.5.3301E Boehringer Ingelheim Investigational Site
    Le Temple de Bretagne, France
  • 1235.5.3309F Boehringer Ingelheim Investigational Site
    Les Ponts de CE, France
  • 1235.5.3307G Boehringer Ingelheim Investigational Site
    Loudun, France
  • 1235.5.3305B Boehringer Ingelheim Investigational Site
    Louvigné le Bais, France
  • 1235.5.3307E Boehringer Ingelheim Investigational Site
    Mouliherne, France
  • 1235.5.3306A Boehringer Ingelheim Investigational Site
    Murs Erigne, France
  • 1235.5.3307A Boehringer Ingelheim Investigational Site
    Murs-Erigne, France
  • 1235.5.3301A Boehringer Ingelheim Investigational Site
    Nantes, France
  • 1235.5.3301B Boehringer Ingelheim Investigational Site
    Nantes, France
  • 1235.5.3301D Boehringer Ingelheim Investigational Site
    Nantes, France
  • 1235.5.3301M Boehringer Ingelheim Investigational Site
    Nantes, France
  • 1235.5.3302A Boehringer Ingelheim Investigational Site
    Nevers, France
  • 1235.5.3302F Boehringer Ingelheim Investigational Site
    Nevers, France
  • 1235.5.3301I Boehringer Ingelheim Investigational Site
    Nort sur Erdre, France
  • 1235.5.3301C Boehringer Ingelheim Investigational Site
    Orvault, France
  • 1235.5.3307F Boehringer Ingelheim Investigational Site
    Parcay les Pins, France
  • 1235.5.3307C Boehringer Ingelheim Investigational Site
    Saint Pierre Montlimard, France
  • 1235.5.3301N Boehringer Ingelheim Investigational Site
    Sautron, France
  • 1235.5.3306B Boehringer Ingelheim Investigational Site
    Segre, France
  • 1235.5.3301F Boehringer Ingelheim Investigational Site
    St Aubin les Châteaux, France
  • 1235.5.3306F Boehringer Ingelheim Investigational Site
    St Georges de Montaigu, France
  • 1235.5.3304B Boehringer Ingelheim Investigational Site
    St Ouen La Rouerie, France
  • 1235.5.3306E Boehringer Ingelheim Investigational Site
    Thouars, France
  • 1235.5.3304C Boehringer Ingelheim Investigational Site
    Tinténiac, France
  • 1235.5.3303A Boehringer Ingelheim Investigational Site
    Vannes, France
  • 1235.5.3308A Boehringer Ingelheim Investigational Site
    Vihiers, France
  • 1235.5.82007 Boehringer Ingelheim Investigational Site
    Busan, Korea, Republic of
  • 1235.5.82001 Boehringer Ingelheim Investigational Site
    Daegu, Korea, Republic of
  • 1235.5.82006 Boehringer Ingelheim Investigational Site
    Daejon, Korea, Republic of
  • 1235.5.82004 Boehringer Ingelheim Investigational Site
    Gangwon-Do, Korea, Republic of
  • 1235.5.82008 Boehringer Ingelheim Investigational Site
    Gwangju, Korea, Republic of
  • 1235.5.82002 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1235.5.82003 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1235.5.82005 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1235.5.31008 Boehringer Ingelheim Investigational Site
    Beerzerveld, Netherlands
  • 1235.5.31006 Boehringer Ingelheim Investigational Site
    Bennebroek, Netherlands
  • 1235.5.31004 Boehringer Ingelheim Investigational Site
    Hoogwoud, Netherlands
  • 1235.5.31003 Boehringer Ingelheim Investigational Site
    Musselkanaal, Netherlands
  • 1235.5.31007 Boehringer Ingelheim Investigational Site
    Nijverdal, Netherlands
  • 1235.5.31001 Boehringer Ingelheim Investigational Site
    Oude Pekela, Netherlands
  • 1235.5.31005 Boehringer Ingelheim Investigational Site
    Roelofarendsveen, Netherlands
  • 1235.5.31010 Boehringer Ingelheim Investigational Site
    Voerendaal, Netherlands
  • 1235.5.47002 Boehringer Ingelheim Investigational Site
    Bergen, Norway

Showing the first 100 of 129 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007 and a primary completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2007
First posted
Nov 15, 2007
Start
Oct 2007
Primary completionActual
Sep 2008
Results first posted
Dec 15, 2009
Last update
Jun 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00558428
First posted
Nov 15, 2007
Start date
Oct 2007
Primary completion
Sep 2008
Results posted
Dec 15, 2009
Last update
Jun 27, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion